CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Saved in:
Bibliographic Details
Title: CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.
Authors: Zhang S; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA., Ozer BH; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Omuro A; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA., Yuan Y; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA (Y.Y.)., Mendoza T; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Wall K; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Grajkowska E; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Vera E; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Reyes J; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Aldape K; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA (K.A.)., Penas-Prado M; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wu J; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Burton EC; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Walbert T; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mikkelsen T; Department of Neurology and Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA., Weathers SP; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., O'Brien B; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., de Groot J; Department of Neurology and Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA., Puduvalli V; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DeAngelis L; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Pentsova E; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Kaley TJ; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Gavrilovic I; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Gerstner ER; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA., Armstrong TS; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Gilbert MR; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Source: Neuro-oncology advances [Neurooncol Adv] 2026 Mar 09; Vol. 8 (1), pp. vdag016. Date of Electronic Publication: 2026 Mar 09 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2632-2498
DOI:10.1093/noajnl/vdag016